🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "significant breakthrough" in the battle against increasingly resistant strains of the bacteria, according to health experts.

A Global Health Concern

Gonorrhoea infections are on the rise around the world, with estimates suggesting over 82 million instances per year. Notably increased rates are reported in Africa and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune step in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce available drugs currently available.”

Health officials are deeply concerned about the increase in antibiotic-resistant strains. The global health body has classified it as a "critical concern". Recent surveillance found that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

One new antibiotic, marketed under the name a brand name, was authorized by the US FDA in December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists believe that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GSK, gained clearance in the same week. This treatment, which is also used to treat UTIs, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the drug firm Innoviva to develop it.

“This approval represents a huge turning point in the treatment of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Research Study Outcomes and Global Access

As per findings detailed in a major medical journal, the new drug eradicated more than 90% of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which combines two antibiotics. The research involved hundreds of volunteers from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals treating patients have voiced optimism. Access to a one-pill regimen like this is seen as a "game-changer" for gonorrhoea control. This is viewed as crucial to reduce the burden of the disease for patients and to prevent the spread of untreatable gonorrhoea around the world.